Litcius/Paper detail

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann, Johann S. de Bono, Neal D. Shore, Kim N., Michael J. Crosby, Josep M. Piulats, Aude Fléchon, Xiao X. Wei, Hakim Mahammedi, Guilhem Roubaud, Hana Študentová, James Nagarajah, Begoña Mellado, Álvaro Montesa-Pino, Euloge Kpamegan, Samson Ghebremariam, Teri Kreisl, Celine Wilke, Katja Lehnhoff, Oliver Sartor, Karim Fizazi

2024The Lancet261 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTaxaneProstate cancerOncologyAndrogen receptorInternal medicineAndrogen deprivation therapyClinical trialCancerBreast cancerProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial | Litcius